Among seven new medicines recommended for approval by the EMA's human medicine advisory committee at its latest meeting is GSK's depemokimab, a long-acting anti-IL-5 antibody for severe asthma and an ...

SteQeyma ™ 45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, which will facilitate subcutaneous administration in patients with plaque psoriasis, ...

GSK plc announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of Nucala (mepolizumab), a monoclonal antibody ...

GSK plc GSK announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a positive opinion recommending the approval of Nucala as an ...

(Alliance News) - GSK PLC on Friday said the Committee for Medicinal Products for Human Use of the European Medicines Agency recommended the approval of depemokimab in two indications. The ...

· Positive opinion based on MATINEE phase III trial showing significant reduction in COPD exacerbations versus placebo in addition to inhaled triple therapy · Nucala is the only monthly biologic ...

LONDON - GSK plc (LSE/NYSE:GSK) announced Friday that its monoclonal antibody Nucala (mepolizumab) has received a positive recommendation from the European Medicines Agency’s Committee for Medicinal ...

Sempresto, Inc., a medical device company pioneering smartphone integrated rescue drug delivery, today announced the acquisition of Alerje’s mobile device integrated auto-injector platform, including ...

Please provide your email address to receive an email when new articles are posted on . Feasibility and acceptability scores for the autoinjector were highest among health care professionals. All ...

A new mold concept developed by Zahoransky is engineered to accelerate the mass production of housings for insulin pens and auto injectors in a space- and energy-efficient manner. The Z.Sonic turn ...

GSK’s respiratory drug lineup spans a newly approved product for chronic obstructive pulmonary disease as well as therapeutic candidates in various stages of clinical development for treating this ...

This is read by an automated voice. Please report any issues or inconsistencies here. A rare-disease patient questions what drives research costs behind $41,000-per-month medication, even before FDA ...